$50 million to scale drill-free dental treatments

Today, tooth decay remains the number one non-communicable disease in the world, according to the World Health Organization. vVARDIS founders Haley and Goly Abivardi address this epidemic with groundbreaking biomimetic, non-invasive solutions for dental professionals under the Curodont™ brand. Using a proprietary biomimetic formulation, Curodont™ is a clinically proven treatment that helps arrest the progression of and repair early tooth decay without the need of a drill. It replicates and builds on the body’s natural defences, working together with minerals in the saliva to repair the damage done to the tooth in the early stages of tooth decay.

With more than one million teeth treated in the United States since January 2024, vVARDIS is currently the fastest-growing dental manufacturer in its industry. Last year’s rapid expansion of sales in the U.S. has already driven nearly 10 percent of dental practices to purchase the product and treat more than 400,000 patients since 2024.

Healthcare venture Capital firm OrbiMed has invested an additional $50 million into the startup, building on its initial $35 million investment, which closed in February. The total capital of $85 million will be used to refinance existing facilities and support the company’s growth initiatives and continued global commercial expansion of innovative dental products under the Curodont™ brand, vVARDIS’ groundbreaking drill-free treatment for early tooth decay.

“After our initial investment, we’ve seen firsthand the momentum vVARDIS is building in the dental market with its Curodont™ products,” said Matthew Rizzo, General Partner, OrbiMed. “We came in at a pivotal moment-just as the product began gaining real traction-and the company’s rapid progress and the market’s response have since reinforced our belief in the significant opportunities ahead. That’s why we’re excited to deepen our commitment and expand our investment to support vVARDIS in its next phase of growth.”

Haley and Goly Abivardi, founders and co-CEOs of vVARDIS, said: “We are thrilled to expand our partnership with OrbiMed as we enter this next phase of growth. With Curodont™ now offered in nearly 10 percent of U.S. dental offices, it’s clear dental professionals are embracing our solution for early decay. This additional funding, combined with OrbiMed’s strategic expertise, will accelerate our ability to serve dental professionals and patients globally. As dentists, we are delighted to bring forward a drill-free treatment for early decay that promises to elevate the standard of care for patients around the world.”

Source: https://www.startupticker.ch